tirzepatide and semaglutide peptide or small molecule vs. Semaglutide: Key Differences in Metabolic Research Tirzepatide, a dual GIP/GLP-1 receptor

Rodent studies have shown that treatment with liraglutide or once-weekly exenatide is associated with thyroid C-cell proliferation and the formation of thyroid C-cell tumors ( Therefore, the US Food and Drug Administration (FDA) prohibits these therapies for patients with an individual or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome type 2 (MEN2)

Compounded formulations may seem legitimate

For now, I just noticed this

Mol Cell Endocrinol (2022) 542:111529

Current information is accurate as of July 2026, and researchers should consult official regulatory resources for the latest guidance relevant to their jurisdiction